上海凯赛生物技术股份有限公司 2024 年年度股东大会会议资料 证券代码：688065 证券简称：凯赛生物 上海凯赛生物技术股份有限公司 2024 年年度股东大会会议资料 中国·上海 二〇二五年六月二十七日 | | | 上海凯赛生物技术股份有限公司 2024 年年度股东大会会议资料 上海凯赛生物技术股份有限公司 地址：中国（上海）自由贸易试验区蔡伦路 1690 号 5 幢 邮编：201203 电话：86-21-50801916 传真：86-21-50801386 网站：http://www.cathaybiotech.com 上海凯赛生物技术股份有限公司 2024 年年度股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 本次股东大会顺利召开，根据《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司股东大会规则》以及《上海凯赛生物技术股份有限公司章程》等 有关规定，特制定本次股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、请出席大会的股东或其代理人或其他出席者 ...

Core Points - The annual general meeting of Shanghai Cathay Biotech Co., Ltd. is scheduled for June 27, 2025, at 14:00, combining on-site and online voting methods [3][4] - The company reported a significant increase in revenue and net profit for 2024, with total revenue reaching CNY 2,957.91 million, a 39.91% increase year-on-year, and net profit attributable to shareholders amounting to CNY 488.96 million, a 33.41% increase [16][32] - The company plans to distribute a cash dividend of CNY 4.00 per 10 shares, totaling CNY 287.58 million, based on the audited net profit for 2024 [8][9] Meeting Procedures - Attendees must register and confirm their attendance before the meeting starts, and they are required to present their shareholder certificates to enter the venue [2][3] - The meeting will include the election of monitors and counters, the presentation of the independent directors' report, and the discussion of various proposals [4][6][11] Financial Performance - The company achieved a net profit of CNY 488.96 million in 2024, with a significant increase in net profit excluding non-recurring gains and losses, which rose by 51.60% to CNY 464.73 million [16][32] - The total assets of the company reached CNY 19.02 billion, reflecting a stable financial position [32] Strategic Developments - The company has successfully introduced CNY 5.915 billion in funding through a directed issuance of shares to enhance its business development [18] - A strategic cooperation agreement was signed with Hefei Municipal Government and China Merchants Innovation Technology Group to establish a synthetic biological materials industry cluster [18][28] Governance and Compliance - The board of directors and the supervisory board have actively fulfilled their responsibilities, ensuring compliance with relevant laws and regulations [19][25] - The company has maintained a high standard of information disclosure, achieving an A-level rating for its disclosure practices in the Shanghai Stock Exchange [23][26]

Core Insights - The Ministry of Industry and Information Technology and the National Development and Reform Commission have initiated a program to cultivate over 20 pilot platforms for biomanufacturing by 2027, aiming to facilitate industrial scale-up [1] - Significant technological breakthroughs and industrial layouts are emerging in the biomanufacturing sector, with advancements in areas such as polysulfone plastic recycling and wool sterol synthesis [1] - The synergy between policy support and industrial development is accelerating the transition of biomanufacturing from laboratory research to large-scale industrialization, showcasing a vibrant development chain of "technological breakthroughs - policy support - capital influx" [1] Industry Developments - Synthetic biology is reshaping production models in biomanufacturing, enabling tasks that traditional biotechnologies cannot achieve, while also providing more efficient and environmentally friendly biosynthesis solutions [1] - Companies like Huaxi Biological and Yikole are extending their capabilities in synthetic biology, with Huaxi focusing on the supply chain of hyaluronic acid and Yikole leveraging CRISPR-Cas9 technology for precise gene editing [2][3] - The integration of synthetic biology with traditional industries is seen as a means to enhance productivity and create new growth opportunities, rather than a conflict [4] Technological Innovations - Companies are developing comprehensive systems in synthetic biology, focusing on tool, platform, and product integration, with significant advancements in production efficiency [3] - AI is playing a crucial role in enhancing research efficiency in synthetic biology, with companies establishing AI teams to optimize data collection and algorithm development [7] - The use of AI in the design and testing phases of synthetic biology is expected to significantly reduce research timelines and costs, improving overall productivity [7] Market Trends - The biomanufacturing industry is experiencing a wave of policy support, with various local governments implementing initiatives to promote the industrialization of synthetic biology [8] - The market for biomanufacturing in China is projected to approach 1.8 trillion yuan by 2030, indicating substantial growth potential [8] - Recent financing trends show an acceleration in investments in domestic synthetic biology companies, with nearly a hundred firms securing new funding at the beginning of 2025 [8] Future Outlook - The synthetic biology sector is anticipated to undergo rapid technological iterations and deeper application expansions in the next 3-5 years, driven by AI advancements [9] - Companies are encouraged to focus on quality improvement and original design rather than mere scale expansion, to avoid resource wastage and industry chaos [9] - The industry is expected to face dual challenges in technology transfer and industrialization, particularly in constructing microbial cell factories and overcoming engineering challenges in fermentation and purification [10]

Core Viewpoint - The chemical new materials industry is expected to enter a rapid growth phase driven by policy support, industrial transformation, and increasing domestic demand for high-performance materials in sectors such as semiconductors, electronics, and renewable energy [2][11][12]. Group 1: Industry Growth and Market Potential - The global chemical new materials market was valued at approximately $370 billion in 2019 and is projected to reach $480 billion by 2025, with a CAGR of about 4.4% [3][16]. - The domestic market for chemical new materials is estimated to grow from approximately 900 billion yuan in 2019 to 1.5 trillion yuan by 2025, reflecting a CAGR of 8.6% [3][25]. - The demand for chemical new materials is expected to continue growing due to the transformation and upgrading of industries such as semiconductors, electronics, and renewable energy [3][25]. Group 2: Policy Support and Technological Advancements - The Chinese government has increased support for high-end manufacturing and new materials since the US-China trade tensions began in 2018, with policies aimed at promoting self-sufficiency in the supply chain [2][12]. - The Ministry of Industry and Information Technology released a directory in December 2021 that includes over 300 types of new materials, highlighting the government's commitment to advancing this sector [4][12]. - Domestic companies have significantly increased their R&D investments, with a reported 17 billion euros in 2019, reflecting a CAGR of 36% from 2014 to 2019 [4][27]. Group 3: Domestic Industry Landscape - The domestic chemical new materials industry has a strong foundation, with a market value of approximately 600 billion yuan in 2019, but still relies heavily on imports for high-end products [17]. - Key domestic players such as Wanhua Chemical, Hualu Hengsheng, and Jinhai Technology are making strides in the new materials sector through innovation and technology adoption [33]. - The industry is characterized by a significant opportunity for domestic substitution, particularly in high-end polyolefins, engineering plastics, and functional films, where self-sufficiency remains low [17][19]. Group 4: Emerging Opportunities and Trends - The demand for high-performance fibers, films, and electronic chemicals is expected to grow rapidly, driven by advancements in sectors like renewable energy and electronics [5][25]. - Emerging materials such as aerogels and biobased materials are gaining traction, with domestic companies positioned to capture early market share in these innovative fields [5][19]. - The lifecycle of many new materials in China is still in the early stages, indicating substantial room for growth and development compared to more mature markets in developed countries [19][20].

证券代码：688065 证券简称：凯赛生物 公告编号：2025-028 上海凯赛生物技术股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/22 ， 由 原 控 | | 公 | 司 | | 股 | 股 | 东 | Cathay | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | Industrial Biotech Ltd.提议 | | | | | | | | | | 回购方案实施期限 | 2024 年 月 21 日~2025 年 | 10 | | | 10 | 月 | 20 | 日 | | | 预计回购金额 | 1,000万元~2,000万元 | | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | | | □用于转换公司可转债 | | | | | | | | | | | □ ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-031 上海凯赛生物技术股份有限公司 续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：天健会计师事务所（特殊普通合伙） 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2025 年 6 月 4 日 召开第二届董事会第三十二次会议，审议通过了《关于续聘 2025 年度审计机构 的议案》，公司拟继续聘任天健会计师事务所（特殊普通合伙）（以下简称"天健"） 为公司 2025 年度财务及内部控制审计机构，该议案尚需提请公司 2024 年年度股 东大会审议。现将相关事宜公告如下： 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | --- | --- | --- | | 成立日期 | 2011 年 7 月 18 日 | 组织形式 特殊普通合伙 | | 注册地址 | 浙江省杭州市西湖区西溪路 | 128 号 6 楼 | | 首席合 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-030 上海凯赛生物技术股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 27 日 至2025 年 6 月 27 日 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 召开日期时间：2025 年 6 月 27 日 14 点 00 分 召开地点：上海市闵行区绿洲环路 396 弄 11 号 9 楼会议室 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 股东大会召开日期：2025年6月27日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 证券代码：688065 证券简称：凯赛生物 公告编号：2025-029 上海凯赛生物技术股份有限公司 第二届监事会第二十六次会议决议公告 表决结果：3票同意；0票反对；0票弃权。 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《关于 续聘会计师事务所的公告》（公告编号：2025-031）。 特此公告。 上海凯赛生物技术股份有限公司 监 事 会 2025 年 6 月 5 日 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2025 年 5 月 25 日向全 体监事以邮件方式发出会议通知，并于 2025 年 6 月 4 日 15:00 以通讯会议的方式召 开第二届监事会第二十六次会议。本次会议由监事会主席张国华主持，会议应到 3 人， 实到 3 人。本次会议的召集、召开符合《中华人民共和国公司法》等法律、法规、规 章、规范性文件和《公司章程》的有关规定，表决形成的决议合法、有效。 二、监事会会议审议情况 审议通过《关于续 ...

Core Viewpoint - The new materials industry in China is experiencing rapid growth driven by policy support, market demand, and technological innovation, with a projected total output value of 8.48 trillion yuan in 2024, maintaining double-digit growth for 14 consecutive years [1][3][20]. Group 1: Industry Definition and Classification - New materials refer to recently developed or developing structural and functional materials with superior properties. They can be classified into structural materials and functional materials based on their usage, and further categorized into four types: metal materials, inorganic non-metal materials, organic polymer materials, and advanced composite materials [1]. Group 2: Current Development Status - The new materials industry has expanded significantly, with the government focusing on electronic information materials, aerospace materials, new energy materials, and environmentally friendly materials. National high-tech industrial bases for new materials have been established in seven cities [3][5]. Group 3: Market Size and Structure - In 2024, the chemical new materials market is expected to account for approximately 22.08% of the total new materials market in China, while battery new materials will represent about 6.66%. By 2025, these figures are projected to be 21.75% and 6.97%, respectively [7]. Group 4: Competitive Landscape - Major companies in the new materials sector include Lens Technology, Antai Technology, China National Materials, and others, which are enhancing their international competitiveness through technological innovation and market expansion [12][16]. Group 5: Development Trends - The demand for new materials is increasing due to the rapid development of downstream industries such as information technology and new energy. The industry is transitioning towards low-carbon and green development, supported by significant technological advancements [20][23].

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由作者重新编写，仅作新材料相关领域介绍，本文 不构成任何投资建议！转载请注明来源！ 5月20日， 凯赛生物 在投资者互动平台上表示， 目前公司位于山西合成生物产业园的项目建设正在进 行中，受园区配套基础设施规划变动影响，公司年产90万吨生物基聚酰胺项目有所延期， 但项目的一 部分—— 年产5000吨生物基高温聚酰胺生产线 已经建成，可满足目前连续纤维复合材料开发的需求 。 公司在合肥规划建设的 Bio-PPA CFRT生产基地 也已经开始建设。 关于凯赛生物山西合成生物产业园项目 据了解，凯赛生物与山西综改示范区管委会于 2020年10月签署合作协议，合力打造"山西合成生物产业 生态园"，计划 总投资规模为800亿元 ，其中一期投资计划投资450亿元，二期计划投资 350 亿元。 核心项目 包括240万吨玉米深加工项目及 500 万吨 / 年生物发酵液项目、年产 50 万吨生物基戊二胺项 目、年产 90 万吨生物基聚酰胺项目和年产 8 万吨生物基长链二元酸项目（含 4 万吨生物法癸二酸项 目）。达产后产值将达千亿元以上。 项目详情： 凯赛 ...